SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Dishman Carbogen Amcis Ltd

BSE: 540701 NSE: DCAL ISIN: INE385W01011
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Dishman Carbogen Amcis Ltd belong to?
Dishman Carbogen Amcis Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Dishman Carbogen Amcis Ltd a good quality company?
Dishman Carbogen Amcis Ltd is a weak quality company, based on a inconsistent 10 year financial track record.
Q.3 Is Dishman Carbogen Amcis Ltd undervalued or overvalued?
Dishman Carbogen Amcis Ltd appears Undervalued, as its key valuation ratios are below with their past averages.
Q.4 Is Dishman Carbogen Amcis Ltd a good buy now?
Dishman Carbogen Amcis Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Dishman Carbogen Amcis Ltd?
Dishman Carbogen Amcis Ltd revenue growth is 3.7% for FY-2025 , which is below its 5 year CAGR of 5.8% , indicating slower growth.
Q.2 Gross Profit margin of Dishman Carbogen Amcis Ltd?
Dishman Carbogen Amcis Ltd Gross profit margin which is the profit after deduction of direct costs, is 12.2% for FY-2025 , which is in line with its 5 year median of 12.2% , indicating stable margins.
Q.3 Operating Profit Margin of Dishman Carbogen Amcis Ltd?
Dishman Carbogen Amcis Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 16.64% for FY-2025 , which is above its 5 year median of 15.5% indicating increasing margins.
Q.4 Net Profit Margin of Dishman Carbogen Amcis Ltd?
Dishman Carbogen Amcis Ltd Net Profit Margin is 0.12% for FY-2025 , is above with its 5 year median of -1.24%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 12.2 12.2
Operating Profit Margin 16.64 15.5
Net Profit Margin 0.12 -1.24
Q.5 Return on Asset of Dishman Carbogen Amcis Ltd?
Dishman Carbogen Amcis Ltd Return on Asset is 0.03%, which is above its 5 year historical median of -0.33%, indicating improved asset utilization efficiency.
Q.6 Return on Equity (ROE) of Dishman Carbogen Amcis Ltd?
Dishman Carbogen Amcis Ltd Return on equity is 0.06% for FY-2025 , which is above its historical median of -0.52%, indicating the business is making better use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Dishman Carbogen Amcis Ltd?
Dishman Carbogen Amcis Ltd Return on capital employed is 2.31% for FY-2025 , which is below its estimated weighted average cost of capital(WACC) 14%, indicating value preservation.
Q.8 Cash conversion cycle of Dishman Carbogen Amcis Ltd?
Dishman Carbogen Amcis Ltd Cash conversion cycle is 162 days, above its historical median of 156 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.28 0.27
ROE 0.06 -0.52
ROCE 2.31 0.43
Cash Conversion Cycle 162 days 156 days
Q.9 Debt to Equity ratio of Dishman Carbogen Amcis Ltd?
Dishman Carbogen Amcis Ltd Debt-to-Equity ratio is 0.36 , which is above with the industry average of 0.15 , indicating higher debt levels in the industry.
Q.10 Debt to cash flow from operations of Dishman Carbogen Amcis Ltd?
Dishman Carbogen Amcis Ltd Debt to cash flow from operations is 5.55 , which is at a unhealthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Dishman Carbogen Amcis Ltd?
Promoters hold 59.32% of the Dishman Carbogen Amcis Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Dishman Carbogen Amcis Ltd vs industry peers?
Dishman Carbogen Amcis Ltd revenue CAGR is 5.82% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 2,711.5 137.1
Gross Profit 330.9 15.1
Operating Profit 440 16
Net Profit 3 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.28 0.8
ROE 0.06 8.91
ROCE 2.31 11.59
Cash Conversion Cycle (days) 162.27 76

Valuation & price assessment

Q.1 Stock return of Dishman Carbogen Amcis Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of 6.42% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price - 6.4% 8.3% -19.8%
Q.3 Valuation ratios of Dishman Carbogen Amcis Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 22.51 0.00 40.28
Price to Book 0.42 0.60 2.77
Price to Sales 0.96 1.72 2.65
EV to EBITDA 7.14 11.58 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×